Novo Nordisk A/S-B reported Q1 operating profit of 32.86B Danish crowns, beating forecasts of 28.74B crowns on Wednesday morning. The results were driven by sales of its weight-loss pill, which reached 2.26B crowns and nearly doubled analyst expectations. The performance signals a potential recovery as the drugmaker attempts to reclaim market share from its primary rival in the United States.

Wegovy Pill Drives Revenue Recovery